InterMune

InterMune is a values-driven organization that works to embody integrity, passion, accountability, creativity and teamwork in bringing new treatments and hope to patients and families around the world. Our focus is research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), a progressive, irreversible, unpredictable and ultimately fatal lung disease. Pirfenidone, the only medicine approved for IPF, is marketed by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.